Showing 2251-2260 of 2527 results for "".
- Novartis Asks Workers in Europe, US and Canada to Work From Homehttps://modernod.com/news/novartis-asks-workers-in-europe-us-and-canada-to-work-from-home/2477394/Due to the COVID-19 outbreak, Novartis released a statement requesting that effective today, its associates within the United States, Europe, and Canada to work from home, with the exception of those working in laboratories, manufacturing sites, and in the field. The measure is valid for 3
- Reichert Technologies Signs Exclusive Deal for CATS Reusable Tonometer Prismshttps://modernod.com/news/reichert-technologies-signs-exclusive-deal-for-cats-reusable-tonometer-prisms/2477372/Reichert Technologies has announced its exclusive partnership with CATS Tonometer to distribute the CATS Reusable Tonometer Prism in the United States. The patented CATS Tonometer Prism is superior in IOP accuracy to traditional Goldmann prism, according to a company news release. “For dec
- ImprimisRx Announces Supply Agreement with iOR Partnershttps://modernod.com/news/imprimisrx-announces-supply-agreement-with-ior-partners/2477364/ImprimisRx announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt and various injectable and topical products.
- Kala Pharmaceuticals Announces Statistically Significant Results in STRIDE 3 Trial of Dry Eye Disease Drug Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-statistically-significant-results-in-stride-3-trial-of-dry-eye-disease-drug-eysuvis/2477360/Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met b
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for AMDhttps://modernod.com/news/gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-amd/2477327/Gemini Therapeutics announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients d
- Allergan, Sightsavers, and the IAPB Announce the “Keep Sight” Initiative to Address Glaucoma in Ganjam, Odishahttps://modernod.com/news/allergan-sightsavers-and-the-iapb-announce-the-keep-sight-initiative-to-address-glaucoma-in-ganjam-odisha/2477318/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) announced the launch of its unique joint initiative, ‘Keep Sight India,’ a community-based glaucoma screening program to prevent glaucoma-related vision loss in Ganjam District, Odisha. The pilot kicked off
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdownhttps://modernod.com/news/abbvie-allergan-deal-foes-try-again-to-spur-an-ftc-crackdown/2477311/AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance